Cyclophosphamide in Drosophila promotes genes and transposable elements differential expression and mitochondrial...

Area of Science:

• Toxicology
• Genomics
• Molecular Biology

Background:

• Cyclophosphamide (CPA) is a widely used alkylating agent for cancer, transplantation, and autoimmune diseases.
• Understanding CPA's molecular mechanisms and potential toxicities is crucial for optimizing its therapeutic use.

Purpose of the Study:

• To investigate the effects of acute and chronic Cyclophosphamide (CPA) exposure on gene expression and mitochondrial function in Drosophila melanogaster.
• To identify specific biological pathways and genetic elements affected by CPA treatment.

Main Methods:

• mRNA sequencing was employed to analyze global gene expression changes in Drosophila melanogaster.
• High-resolution respirometry was used to assess mitochondrial function.
• Differential gene expression analysis was conducted using Cufflinks-Cuffdiff, DESeq2, and edgeR.

Main Results:

• CPA significantly altered gene expression, impacting pathways related to stress response, immunity, oxidation-reduction, apoptosis, and cuticle formation.
• This study provides the first evidence of CPA-induced mitochondrial dysfunction due to the downregulation of mitochondrial genes.
• CPA treatment modulated the transcription of transposable elements (TEs) from the gypsy and copia superfamilies.

Conclusions:

• Cyclophosphamide (CPA) exhibits mitochondrial toxicity through the downregulation of critical mitochondrial genes.
• CPA exposure can alter transposable element transcription patterns in Drosophila.
• These findings elucidate novel mechanisms of CPA toxicity and its impact on the genome.